Is contrast-enhanced mammography (CEM) an alternative to MRI in assessing the response to primary systemic therapy of breast cancer?
•CEM was found to be as accurate as MRI in predicting response to PST.•MRI predict the size of the residual tumor more accurately than CEM.•Some lesions located posteriorly in the breast were not fully included in the CEM views.•Further research is necessary to identify differences among histologica...
Saved in:
Published in: | European journal of radiology Vol. 170; p. 111270 |
---|---|
Main Authors: | , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Ireland
Elsevier B.V
01-01-2024
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | •CEM was found to be as accurate as MRI in predicting response to PST.•MRI predict the size of the residual tumor more accurately than CEM.•Some lesions located posteriorly in the breast were not fully included in the CEM views.•Further research is necessary to identify differences among histological subgroups.
To evaluate the accuracy of contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) in the assessing radiological response to primary systemic therapy (PST).
Prospective study between February 2021 and October 2022. Women with breast cancer and indication of PST were enrolled. CEM and MRI were performed before and after PST, and the findings, including size and radiological response pattern, were compared with the size of the residual lesion measured in surgical specimens and its Miller-Payne classification (considered the gold standard). Two of four independent radiologists, with 2 years of CEM experience and 10 years of MRI experience, reviewed the images while being blinded to the results of the other technique. The agreement between measurements was evaluated using the Pearson correlation coefficient (r) and Lin’s coefficient.
Forty-eight women with breast cancer who required PST were enrolled in the study, with a mean age of 57.21 ± 10.14 years. A total of thirty-three participants (68.75 %) completed the study. The correlation between CEM and MRI measurements was high before PST (r: 0.97), and local staging was identical for 45 out of 48 patients. MRI demonstrated better accuracy in predicting residual tumor size than CEM, with Lin’s coefficient 0.91 and 0.73, respectively. However, no significant differences were observed in predicting response to therapy. Both methods tended to overestimate the size and degree of response in our study, with mean overestimations of 2.87 mm in CEM and 0.51 mm in MRI.
CEM was found to be as accurate as MRI in predicting response to PST, indicating its potential as an alternative imaging technique, but further research is necessary. |
---|---|
AbstractList | To evaluate the accuracy of contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) in the assessing radiological response to primary systemic therapy (PST).
Prospective study between February 2021 and October 2022. Women with breast cancer and indication of PST were enrolled. CEM and MRI were performed before and after PST, and the findings, including size and radiological response pattern, were compared with the size of the residual lesion measured in surgical specimens and its Miller-Payne classification (considered the gold standard). Two of four independent radiologists, with 2 years of CEM experience and 10 years of MRI experience, reviewed the images while being blinded to the results of the other technique. The agreement between measurements was evaluated using the Pearson correlation coefficient (r) and Lin's coefficient.
Forty-eight women with breast cancer who required PST were enrolled in the study, with a mean age of 57.21 ± 10.14 years. A total of thirty-three participants (68.75 %) completed the study. The correlation between CEM and MRI measurements was high before PST (r: 0.97), and local staging was identical for 45 out of 48 patients. MRI demonstrated better accuracy in predicting residual tumor size than CEM, with Lin's coefficient 0.91 and 0.73, respectively. However, no significant differences were observed in predicting response to therapy. Both methods tended to overestimate the size and degree of response in our study, with mean overestimations of 2.87 mm in CEM and 0.51 mm in MRI.
CEM was found to be as accurate as MRI in predicting response to PST, indicating its potential as an alternative imaging technique, but further research is necessary. •CEM was found to be as accurate as MRI in predicting response to PST.•MRI predict the size of the residual tumor more accurately than CEM.•Some lesions located posteriorly in the breast were not fully included in the CEM views.•Further research is necessary to identify differences among histological subgroups. To evaluate the accuracy of contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) in the assessing radiological response to primary systemic therapy (PST). Prospective study between February 2021 and October 2022. Women with breast cancer and indication of PST were enrolled. CEM and MRI were performed before and after PST, and the findings, including size and radiological response pattern, were compared with the size of the residual lesion measured in surgical specimens and its Miller-Payne classification (considered the gold standard). Two of four independent radiologists, with 2 years of CEM experience and 10 years of MRI experience, reviewed the images while being blinded to the results of the other technique. The agreement between measurements was evaluated using the Pearson correlation coefficient (r) and Lin’s coefficient. Forty-eight women with breast cancer who required PST were enrolled in the study, with a mean age of 57.21 ± 10.14 years. A total of thirty-three participants (68.75 %) completed the study. The correlation between CEM and MRI measurements was high before PST (r: 0.97), and local staging was identical for 45 out of 48 patients. MRI demonstrated better accuracy in predicting residual tumor size than CEM, with Lin’s coefficient 0.91 and 0.73, respectively. However, no significant differences were observed in predicting response to therapy. Both methods tended to overestimate the size and degree of response in our study, with mean overestimations of 2.87 mm in CEM and 0.51 mm in MRI. CEM was found to be as accurate as MRI in predicting response to PST, indicating its potential as an alternative imaging technique, but further research is necessary. PURPOSETo evaluate the accuracy of contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) in the assessing radiological response to primary systemic therapy (PST).METHODProspective study between February 2021 and October 2022. Women with breast cancer and indication of PST were enrolled. CEM and MRI were performed before and after PST, and the findings, including size and radiological response pattern, were compared with the size of the residual lesion measured in surgical specimens and its Miller-Payne classification (considered the gold standard). Two of four independent radiologists, with 2 years of CEM experience and 10 years of MRI experience, reviewed the images while being blinded to the results of the other technique. The agreement between measurements was evaluated using the Pearson correlation coefficient (r) and Lin's coefficient.RESULTSForty-eight women with breast cancer who required PST were enrolled in the study, with a mean age of 57.21 ± 10.14 years. A total of thirty-three participants (68.75 %) completed the study. The correlation between CEM and MRI measurements was high before PST (r: 0.97), and local staging was identical for 45 out of 48 patients. MRI demonstrated better accuracy in predicting residual tumor size than CEM, with Lin's coefficient 0.91 and 0.73, respectively. However, no significant differences were observed in predicting response to therapy. Both methods tended to overestimate the size and degree of response in our study, with mean overestimations of 2.87 mm in CEM and 0.51 mm in MRI.CONCLUSIONCEM was found to be as accurate as MRI in predicting response to PST, indicating its potential as an alternative imaging technique, but further research is necessary. |
ArticleNumber | 111270 |
Author | Garcia Mur, Carmen Sunen, Ines Isabel Garcia Barrado, Ana Gros Bañeres, Belen Garcia Maroto, Julian Cruz Ciria, Silvia |
Author_xml | – sequence: 1 givenname: Ines surname: Sunen fullname: Sunen, Ines email: isunnena@salud.aragon.es organization: Department of Radiology, Nuestra Señora de Gracia Hospital, Zaragoza, Spain – sequence: 2 givenname: Ana surname: Isabel Garcia Barrado fullname: Isabel Garcia Barrado, Ana organization: Department of Radiology, Miguel Servet Hospital, Zaragoza, Spain – sequence: 3 givenname: Silvia surname: Cruz Ciria fullname: Cruz Ciria, Silvia organization: Department of Radiology, Miguel Servet Hospital, Zaragoza, Spain – sequence: 4 givenname: Julian surname: Garcia Maroto fullname: Garcia Maroto, Julian organization: Department of Radiology, Miguel Servet Hospital, Zaragoza, Spain – sequence: 5 givenname: Belen surname: Gros Bañeres fullname: Gros Bañeres, Belen organization: Department of Emergencies, Miguel Servet Hospital, Zaragoza, Spain – sequence: 6 givenname: Carmen surname: Garcia Mur fullname: Garcia Mur, Carmen organization: Department of Radiology, Miguel Servet Hospital, Zaragoza, Spain |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38141263$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE2LUzEUhoOMOJ3RXyBIluPi1nzc29wsRKSMWphBEAV3ITc5nab0JjUnHejeH27utLp0deDwnPflPFfkIqYIhLzmbM4ZX7zbzmGbrZ8LJuSccy4Ue0ZmvFeiUUqoCzJjSrCGtf3PS3KFuGWMda0WL8il7HnLxULOyO8VUpdiyRZLA3FjowNPRzuO6SHb_eZIb5a392-pjdTuCuRoS3gEWhK9_7aioW4RATHEB1o2QDPgPkV8AvY5jDYfKR6xwBjcBNTII01rOmSohdRNdfnDS_J8bXcIr87zmvz4dPt9-aW5-_p5tfx41zjJdGk8-BbYurfaLuwgQauu90wNftCtW8i2HaRWWvZKK963HizvrRqgqzz3ngt5TW5Oufucfh0AixkDOtjtbIR0QCM06zqhakpF5Ql1OSFmWJvzO4YzM-k3W_Ok30z6zUl_vXpzLjgMI_h_N399V-D9CYD65mOAbNAFmJyHDK4Yn8J_C_4AFqGadA |
Cites_doi | 10.1200/JCO.2015.63.1010 10.1186/s43055-019-0041-8 10.1259/bjr.20200301 10.12659/MSM.893018 10.1016/j.ejrad.2017.11.024 10.1200/JCO.20.03399 10.1016/j.annonc.2021.06.023 10.7150/jca.79747 10.1186/s13058-017-0899-1 10.1177/03008916211050124 10.1007/s00330-013-3007-7 10.1007/s11307-019-01423-5 10.1200/JCO.21.02439 10.1016/S0140-6736(13)62422-8 10.3390/curroncol28050298 10.1093/bjs/znac391 10.1016/j.ejca.2008.10.026 10.1016/S0960-9776(03)00106-1 10.1148/radiol.2021201948 10.1007/s00330-017-5251-8 10.1016/j.breast.2022.01.008 10.1016/j.ejrad.2023.110881 10.1186/s41747-022-00318-5 10.1245/s10434-018-6413-x 10.1259/bjr.20211172 10.1093/annonc/mdy537 10.1053/j.sult.2017.08.005 10.1155/2018/8531916 10.1186/s12885-018-4760-4 10.3390/biomedicines10102384 |
ContentType | Journal Article |
Copyright | 2023 Copyright © 2023. Published by Elsevier B.V. |
Copyright_xml | – notice: 2023 – notice: Copyright © 2023. Published by Elsevier B.V. |
DBID | NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.ejrad.2023.111270 |
DatabaseName | PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1872-7727 |
EndPage | 111270 |
ExternalDocumentID | 10_1016_j_ejrad_2023_111270 38141263 S0720048X23005843 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 4.4 457 4CK 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAWTL AAXUO ABBQC ABFNM ABJNI ABLJU ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEI HMK HMO HVGLF HZ~ IHE J1W KOM M29 M41 MO0 N9A O-L O9- OAUVE OI~ OU0 OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SDF SDG SEL SES SEW SPCBC SSH SSZ T5K UV1 WUQ Z5R ZA5 ZGI ~G- AAXKI AFJKZ NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c309t-ded4e0f8a9a6ab3e9758d07bdb94c6344b397938797184dea18a7be5a9a1dd123 |
ISSN | 0720-048X |
IngestDate | Fri Oct 25 06:36:42 EDT 2024 Thu Sep 26 17:48:18 EDT 2024 Sat Nov 02 12:29:30 EDT 2024 Sat May 04 15:44:33 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | CC PR non-pCR Residual lesion ICC Breast cancer CEM non-CR Complete response CR PST MLO SD contrast-enhanced mammography (CEM) PD NPV BPE DCIS PPV Primary systemic therapy pCR |
Language | English |
License | Copyright © 2023. Published by Elsevier B.V. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c309t-ded4e0f8a9a6ab3e9758d07bdb94c6344b397938797184dea18a7be5a9a1dd123 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 38141263 |
PQID | 2905527397 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | proquest_miscellaneous_2905527397 crossref_primary_10_1016_j_ejrad_2023_111270 pubmed_primary_38141263 elsevier_sciencedirect_doi_10_1016_j_ejrad_2023_111270 |
PublicationCentury | 2000 |
PublicationDate | January 2024 2024-Jan 2024-01-00 20240101 |
PublicationDateYYYYMMDD | 2024-01-01 |
PublicationDate_xml | – month: 01 year: 2024 text: January 2024 |
PublicationDecade | 2020 |
PublicationPlace | Ireland |
PublicationPlace_xml | – name: Ireland |
PublicationTitle | European journal of radiology |
PublicationTitleAlternate | Eur J Radiol |
PublicationYear | 2024 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Patel, Ranjbar, Wu, Pockaj, Li, Zhang (b0145) 2018; 98 Fallenberg, Dromain, Diekmann, Engelken, Krohn, Singh (b0110) 2014; 24 Tang, Xiang, Yang (b0060) 2020; 93 Pfob, Sidey-Gibbons, Rauch, Thomas, Schaefgen, Kuemmel (b0020) 2022; 40 Moustafa, Kamal, Gomaa, Mostafa, Mubarak, El-Adawy (b0140) 2019; 50 Neeter, Robbe, van Nijnatten, Jochelson, Raat, Wildberger (b0040) 2023; 14 Eisenhauer, Therasse, Bogaerts, Schwartz, Sargent, Ford (b0070) 2009; 45 Ogston, Miller, Payne, Hutcheon, Sarkar, Smith (b0075) 2003; 12 Heil, Sinn, Richter, Pfob, Schaefgen, Hennigs (b0130) 2018; 18 Liguori, Depretto, Ciniselli, Citterio, Boffelli, Verderio (b0065) 2022; 108 Patel, Hilal, Covington, Zhang, Kosiorek, Lobbes (b0095) 2018; 25 Łuczyńska, Heinze-Paluchowska, Hendrick, Dyczek, Ryś, Herman (b0105) 2015; 21 Taylor, Burrows, Dessauvagie, Saunders, Ives (b0080) 2023; 96 Korde, Somerfield, Carey, Crews, Denduluri, Hwang (b0010) 2021; 39 Kim, Cho, Shin, Lee, Han, Park (b0115) 2018; 28 Iotti, Ragazzi, Besutti, Marchesi, Ravaioli, Falco (b0160) 2021; 11 Iotti, Ravaioli, Vacondio, Coriani, Caffarri, Sghedoni (b0045) 2017; 19 Symmans, Wei, Gould, Yu, Zhang, Liu (b0035) 2017; 35 Patel, Lobbes, Lewin (b0050) 2018; 39 Steinhof-Radwańska, Grażyńska, Lorek, Gisterek, Barczyk-Gutowska, Bobola (b0100) 2021; 28 Luczynska, Piegza, Szpor, Heinze, Popiela, Kargol (b0125) 2022; 10 Jochelson, Lobbes (b0155) 2021; 299 Lobbes, Neeter, Raat, Turk, Wildberger, van Nijnatten (b0090) 2023; 164 Rossi, Invento, Pesapane, Pagan, Bagnardi, Fusco (b0135) 2023; 110 Pfob, Heil (b0025) 2022; 62 Pereslucha, Wenger, Morris, Aydi (b0120) 2023; 11 Marino, Pinker, Leithner, Sung, Avendano, Morris (b0150) 2020; 22 Burstein, Curigliano, Thürlimann, Weber, Poortmans, Regan (b0015) 2021; 32 G. Curigliano, H.J. Burstein, P.E. Winer, M. Gnant, P. Dubsky, S. Loibl, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2019;30(7):1181. Barra, Sobrinho, Barra, Magalhães, Aguiar, de Albuquerque (b0055) 2018; 2018 Taylor, Burrows, Saunders, Parizel, Ives (b0085) 2023; 7 Cortazar, Zhang, Untch, Mehta, Costantino, Wolmark (b0030) 2014; 384 Iotti (10.1016/j.ejrad.2023.111270_b0045) 2017; 19 Rossi (10.1016/j.ejrad.2023.111270_b0135) 2023; 110 Pereslucha (10.1016/j.ejrad.2023.111270_b0120) 2023; 11 10.1016/j.ejrad.2023.111270_b0005 Symmans (10.1016/j.ejrad.2023.111270_b0035) 2017; 35 Heil (10.1016/j.ejrad.2023.111270_b0130) 2018; 18 Iotti (10.1016/j.ejrad.2023.111270_b0160) 2021; 11 Patel (10.1016/j.ejrad.2023.111270_b0050) 2018; 39 Steinhof-Radwańska (10.1016/j.ejrad.2023.111270_b0100) 2021; 28 Jochelson (10.1016/j.ejrad.2023.111270_b0155) 2021; 299 Moustafa (10.1016/j.ejrad.2023.111270_b0140) 2019; 50 Eisenhauer (10.1016/j.ejrad.2023.111270_b0070) 2009; 45 Ogston (10.1016/j.ejrad.2023.111270_b0075) 2003; 12 Fallenberg (10.1016/j.ejrad.2023.111270_b0110) 2014; 24 Tang (10.1016/j.ejrad.2023.111270_b0060) 2020; 93 Marino (10.1016/j.ejrad.2023.111270_b0150) 2020; 22 Lobbes (10.1016/j.ejrad.2023.111270_b0090) 2023; 164 Burstein (10.1016/j.ejrad.2023.111270_b0015) 2021; 32 Barra (10.1016/j.ejrad.2023.111270_b0055) 2018; 2018 Neeter (10.1016/j.ejrad.2023.111270_b0040) 2023; 14 Pfob (10.1016/j.ejrad.2023.111270_b0025) 2022; 62 Patel (10.1016/j.ejrad.2023.111270_b0145) 2018; 98 Korde (10.1016/j.ejrad.2023.111270_b0010) 2021; 39 Pfob (10.1016/j.ejrad.2023.111270_b0020) 2022; 40 Cortazar (10.1016/j.ejrad.2023.111270_b0030) 2014; 384 Kim (10.1016/j.ejrad.2023.111270_b0115) 2018; 28 Liguori (10.1016/j.ejrad.2023.111270_b0065) 2022; 108 Taylor (10.1016/j.ejrad.2023.111270_b0080) 2023; 96 Taylor (10.1016/j.ejrad.2023.111270_b0085) 2023; 7 Patel (10.1016/j.ejrad.2023.111270_b0095) 2018; 25 Łuczyńska (10.1016/j.ejrad.2023.111270_b0105) 2015; 21 Luczynska (10.1016/j.ejrad.2023.111270_b0125) 2022; 10 |
References_xml | – volume: 12 start-page: 320 year: 2003 end-page: 327 ident: b0075 article-title: A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival publication-title: Breast contributor: fullname: Smith – volume: 14 start-page: 174 year: 2023 end-page: 182 ident: b0040 article-title: Comparing the Diagnostic Performance of Contrast-Enhanced Mammography and Breast MRI: a Systematic Review and Meta-Analysis publication-title: J Cancer. contributor: fullname: Wildberger – volume: 108 start-page: 563 year: 2022 end-page: 571 ident: b0065 article-title: Contrast-enhanced digital mammography and magnetic resonance imaging: reproducibility compared to pathologic anatomy publication-title: Tumori. contributor: fullname: Verderio – volume: 32 start-page: 1216 year: 2021 end-page: 1235 ident: b0015 article-title: Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 publication-title: Ann Oncol. contributor: fullname: Regan – volume: 10 year: 2022 ident: b0125 article-title: Contrast-Enhanced Mammography (CEM) Capability to Distinguish Molecular Breast Cancer Subtypes publication-title: Biomedicines. contributor: fullname: Kargol – volume: 299 start-page: 36 year: 2021 end-page: 48 ident: b0155 article-title: Contrast-enhanced Mammography: State of the Art publication-title: Radiology contributor: fullname: Lobbes – volume: 98 start-page: 207 year: 2018 end-page: 213 ident: b0145 article-title: Computer-aided diagnosis of contrast-enhanced spectral mammography: A feasibility study publication-title: Eur J Radiol. contributor: fullname: Zhang – volume: 22 start-page: 780 year: 2020 end-page: 787 ident: b0150 article-title: Contrast-Enhanced Mammography and Radiomics Analysis for Noninvasive Breast Cancer Characterization: Initial Results publication-title: Mol Imaging Biol. contributor: fullname: Morris – volume: 18 start-page: 851 year: 2018 ident: b0130 article-title: RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial publication-title: BMC Cancer contributor: fullname: Hennigs – volume: 384 start-page: 164 year: 2014 end-page: 172 ident: b0030 article-title: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis publication-title: Lancet contributor: fullname: Wolmark – volume: 35 start-page: 1049 year: 2017 end-page: 1060 ident: b0035 article-title: Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype publication-title: J Clin Oncol. contributor: fullname: Liu – volume: 2018 start-page: 8531916 year: 2018 ident: b0055 article-title: Contrast-Enhanced Mammography (CEM) for Detecting Residual Disease after Neoadjuvant Chemotherapy: A Comparison with Breast Magnetic Resonance Imaging (MRI) publication-title: Biomed Res Int. contributor: fullname: de Albuquerque – volume: 7 start-page: 8 year: 2023 ident: b0085 article-title: Contrast-enhanced mammography (CEM) versus MRI for breast cancer staging: detection of additional malignant lesions not seen on conventional imaging publication-title: Eur Radiol Exp. contributor: fullname: Ives – volume: 164 year: 2023 ident: b0090 article-title: The performance of contrast-enhanced mammography and breast MRI in local preoperative staging of invasive lobular breast cancer publication-title: Eur J Radiol. contributor: fullname: van Nijnatten – volume: 11 year: 2021 ident: b0160 article-title: Accuracy and Reproducibility of Contrast-Enhanced Mammography in the Assessment of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients with Calcifications in the Tumor Bed publication-title: Diagnostics (basel) contributor: fullname: Falco – volume: 110 start-page: 217 year: 2023 end-page: 224 ident: b0135 article-title: Diagnostic performance of image-guided vacuum-assisted breast biopsy after neoadjuvant therapy for breast cancer: prospective pilot study publication-title: Br J Surg. contributor: fullname: Fusco – volume: 50 start-page: 44 year: 2019 ident: b0140 article-title: Quantitative mathematical objective evaluation of contrast-enhanced spectral mammogram in the assessment of response to neoadjuvant chemotherapy and prediction of residual disease in breast cancer publication-title: Egypt. J. Radiol. Nucl. Med. contributor: fullname: El-Adawy – volume: 21 start-page: 1358 year: 2015 end-page: 1367 ident: b0105 article-title: Comparison between breast MRI and contrast-enhanced spectral mammography publication-title: Med Sci Monit. contributor: fullname: Herman – volume: 39 start-page: 1485 year: 2021 end-page: 1505 ident: b0010 article-title: Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline publication-title: J Clin Oncol. contributor: fullname: Hwang – volume: 62 start-page: S7 year: 2022 end-page: s11 ident: b0025 article-title: Breast and axillary surgery after neoadjuvant systemic treatment - A review of clinical routine recommendations and the latest clinical research publication-title: Breast contributor: fullname: Heil – volume: 28 start-page: 3448 year: 2021 end-page: 3462 ident: b0100 article-title: Contrast-Enhanced Spectral Mammography Assessment of Patients Treated with Neoadjuvant Chemotherapy for Breast Cancer publication-title: Curr Oncol. contributor: fullname: Bobola – volume: 45 start-page: 228 year: 2009 end-page: 247 ident: b0070 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer. contributor: fullname: Ford – volume: 11 year: 2023 ident: b0120 article-title: Invasive Lobular Carcinoma: A Review of Imaging Modalities with Special Focus on Pathology Concordance publication-title: Healthcare (basel) contributor: fullname: Aydi – volume: 39 start-page: 70 year: 2018 end-page: 79 ident: b0050 article-title: Contrast Enhanced Spectral Mammography: A Review publication-title: Semin Ultrasound CT MR. contributor: fullname: Lewin – volume: 93 start-page: 20200301 year: 2020 ident: b0060 article-title: The diagnostic performance of CESM and CE-MRI in evaluating the pathological response to neoadjuvant therapy in breast cancer: a systematic review and meta-analysis publication-title: Br J Radiol. contributor: fullname: Yang – volume: 24 start-page: 256 year: 2014 end-page: 264 ident: b0110 article-title: Contrast-enhanced spectral mammography versus MRI: Initial results in the detection of breast cancer and assessment of tumour size publication-title: Eur Radiol. contributor: fullname: Singh – volume: 28 start-page: 2986 year: 2018 end-page: 2995 ident: b0115 article-title: Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour publication-title: Eur Radiol. contributor: fullname: Park – volume: 40 start-page: 1903 year: 2022 end-page: 1915 ident: b0020 article-title: Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery publication-title: J Clin Oncol. contributor: fullname: Kuemmel – volume: 25 start-page: 1350 year: 2018 end-page: 1356 ident: b0095 article-title: Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy publication-title: Ann Surg Oncol. contributor: fullname: Lobbes – volume: 19 start-page: 106 year: 2017 ident: b0045 article-title: Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging publication-title: Breast Cancer Res. contributor: fullname: Sghedoni – volume: 96 start-page: 20211172 year: 2023 ident: b0080 article-title: Accuracy and precision of contrast enhanced mammography versus MRI for predicting breast cancer size: how “good” are they really? publication-title: Br J Radiol. contributor: fullname: Ives – volume: 35 start-page: 1049 issue: 10 year: 2017 ident: 10.1016/j.ejrad.2023.111270_b0035 article-title: Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype publication-title: J Clin Oncol. doi: 10.1200/JCO.2015.63.1010 contributor: fullname: Symmans – volume: 50 start-page: 44 issue: 1 year: 2019 ident: 10.1016/j.ejrad.2023.111270_b0140 article-title: Quantitative mathematical objective evaluation of contrast-enhanced spectral mammogram in the assessment of response to neoadjuvant chemotherapy and prediction of residual disease in breast cancer publication-title: Egypt. J. Radiol. Nucl. Med. doi: 10.1186/s43055-019-0041-8 contributor: fullname: Moustafa – volume: 93 start-page: 20200301 issue: 1112 year: 2020 ident: 10.1016/j.ejrad.2023.111270_b0060 article-title: The diagnostic performance of CESM and CE-MRI in evaluating the pathological response to neoadjuvant therapy in breast cancer: a systematic review and meta-analysis publication-title: Br J Radiol. doi: 10.1259/bjr.20200301 contributor: fullname: Tang – volume: 21 start-page: 1358 year: 2015 ident: 10.1016/j.ejrad.2023.111270_b0105 article-title: Comparison between breast MRI and contrast-enhanced spectral mammography publication-title: Med Sci Monit. doi: 10.12659/MSM.893018 contributor: fullname: Łuczyńska – volume: 98 start-page: 207 year: 2018 ident: 10.1016/j.ejrad.2023.111270_b0145 article-title: Computer-aided diagnosis of contrast-enhanced spectral mammography: A feasibility study publication-title: Eur J Radiol. doi: 10.1016/j.ejrad.2017.11.024 contributor: fullname: Patel – volume: 39 start-page: 1485 issue: 13 year: 2021 ident: 10.1016/j.ejrad.2023.111270_b0010 article-title: Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline publication-title: J Clin Oncol. doi: 10.1200/JCO.20.03399 contributor: fullname: Korde – volume: 11 issue: 3 year: 2021 ident: 10.1016/j.ejrad.2023.111270_b0160 article-title: Accuracy and Reproducibility of Contrast-Enhanced Mammography in the Assessment of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients with Calcifications in the Tumor Bed publication-title: Diagnostics (basel) contributor: fullname: Iotti – volume: 32 start-page: 1216 issue: 10 year: 2021 ident: 10.1016/j.ejrad.2023.111270_b0015 article-title: Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 publication-title: Ann Oncol. doi: 10.1016/j.annonc.2021.06.023 contributor: fullname: Burstein – volume: 14 start-page: 174 issue: 1 year: 2023 ident: 10.1016/j.ejrad.2023.111270_b0040 article-title: Comparing the Diagnostic Performance of Contrast-Enhanced Mammography and Breast MRI: a Systematic Review and Meta-Analysis publication-title: J Cancer. doi: 10.7150/jca.79747 contributor: fullname: Neeter – volume: 19 start-page: 106 issue: 1 year: 2017 ident: 10.1016/j.ejrad.2023.111270_b0045 article-title: Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging publication-title: Breast Cancer Res. doi: 10.1186/s13058-017-0899-1 contributor: fullname: Iotti – volume: 108 start-page: 563 issue: 6 year: 2022 ident: 10.1016/j.ejrad.2023.111270_b0065 article-title: Contrast-enhanced digital mammography and magnetic resonance imaging: reproducibility compared to pathologic anatomy publication-title: Tumori. doi: 10.1177/03008916211050124 contributor: fullname: Liguori – volume: 24 start-page: 256 issue: 1 year: 2014 ident: 10.1016/j.ejrad.2023.111270_b0110 article-title: Contrast-enhanced spectral mammography versus MRI: Initial results in the detection of breast cancer and assessment of tumour size publication-title: Eur Radiol. doi: 10.1007/s00330-013-3007-7 contributor: fullname: Fallenberg – volume: 22 start-page: 780 issue: 3 year: 2020 ident: 10.1016/j.ejrad.2023.111270_b0150 article-title: Contrast-Enhanced Mammography and Radiomics Analysis for Noninvasive Breast Cancer Characterization: Initial Results publication-title: Mol Imaging Biol. doi: 10.1007/s11307-019-01423-5 contributor: fullname: Marino – volume: 40 start-page: 1903 issue: 17 year: 2022 ident: 10.1016/j.ejrad.2023.111270_b0020 article-title: Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery publication-title: J Clin Oncol. doi: 10.1200/JCO.21.02439 contributor: fullname: Pfob – volume: 384 start-page: 164 issue: 9938 year: 2014 ident: 10.1016/j.ejrad.2023.111270_b0030 article-title: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis publication-title: Lancet doi: 10.1016/S0140-6736(13)62422-8 contributor: fullname: Cortazar – volume: 28 start-page: 3448 issue: 5 year: 2021 ident: 10.1016/j.ejrad.2023.111270_b0100 article-title: Contrast-Enhanced Spectral Mammography Assessment of Patients Treated with Neoadjuvant Chemotherapy for Breast Cancer publication-title: Curr Oncol. doi: 10.3390/curroncol28050298 contributor: fullname: Steinhof-Radwańska – volume: 110 start-page: 217 issue: 2 year: 2023 ident: 10.1016/j.ejrad.2023.111270_b0135 article-title: Diagnostic performance of image-guided vacuum-assisted breast biopsy after neoadjuvant therapy for breast cancer: prospective pilot study publication-title: Br J Surg. doi: 10.1093/bjs/znac391 contributor: fullname: Rossi – volume: 45 start-page: 228 issue: 2 year: 2009 ident: 10.1016/j.ejrad.2023.111270_b0070 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer. doi: 10.1016/j.ejca.2008.10.026 contributor: fullname: Eisenhauer – volume: 12 start-page: 320 issue: 5 year: 2003 ident: 10.1016/j.ejrad.2023.111270_b0075 article-title: A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival publication-title: Breast doi: 10.1016/S0960-9776(03)00106-1 contributor: fullname: Ogston – volume: 299 start-page: 36 issue: 1 year: 2021 ident: 10.1016/j.ejrad.2023.111270_b0155 article-title: Contrast-enhanced Mammography: State of the Art publication-title: Radiology doi: 10.1148/radiol.2021201948 contributor: fullname: Jochelson – volume: 28 start-page: 2986 issue: 7 year: 2018 ident: 10.1016/j.ejrad.2023.111270_b0115 article-title: Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour publication-title: Eur Radiol. doi: 10.1007/s00330-017-5251-8 contributor: fullname: Kim – volume: 11 issue: 5 year: 2023 ident: 10.1016/j.ejrad.2023.111270_b0120 article-title: Invasive Lobular Carcinoma: A Review of Imaging Modalities with Special Focus on Pathology Concordance publication-title: Healthcare (basel) contributor: fullname: Pereslucha – volume: 62 start-page: S7 issue: Suppl 1 year: 2022 ident: 10.1016/j.ejrad.2023.111270_b0025 article-title: Breast and axillary surgery after neoadjuvant systemic treatment - A review of clinical routine recommendations and the latest clinical research publication-title: Breast doi: 10.1016/j.breast.2022.01.008 contributor: fullname: Pfob – volume: 164 year: 2023 ident: 10.1016/j.ejrad.2023.111270_b0090 article-title: The performance of contrast-enhanced mammography and breast MRI in local preoperative staging of invasive lobular breast cancer publication-title: Eur J Radiol. doi: 10.1016/j.ejrad.2023.110881 contributor: fullname: Lobbes – volume: 7 start-page: 8 issue: 1 year: 2023 ident: 10.1016/j.ejrad.2023.111270_b0085 article-title: Contrast-enhanced mammography (CEM) versus MRI for breast cancer staging: detection of additional malignant lesions not seen on conventional imaging publication-title: Eur Radiol Exp. doi: 10.1186/s41747-022-00318-5 contributor: fullname: Taylor – volume: 25 start-page: 1350 issue: 5 year: 2018 ident: 10.1016/j.ejrad.2023.111270_b0095 article-title: Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy publication-title: Ann Surg Oncol. doi: 10.1245/s10434-018-6413-x contributor: fullname: Patel – volume: 96 start-page: 20211172 issue: 1144 year: 2023 ident: 10.1016/j.ejrad.2023.111270_b0080 article-title: Accuracy and precision of contrast enhanced mammography versus MRI for predicting breast cancer size: how “good” are they really? publication-title: Br J Radiol. doi: 10.1259/bjr.20211172 contributor: fullname: Taylor – ident: 10.1016/j.ejrad.2023.111270_b0005 doi: 10.1093/annonc/mdy537 – volume: 39 start-page: 70 issue: 1 year: 2018 ident: 10.1016/j.ejrad.2023.111270_b0050 article-title: Contrast Enhanced Spectral Mammography: A Review publication-title: Semin Ultrasound CT MR. doi: 10.1053/j.sult.2017.08.005 contributor: fullname: Patel – volume: 2018 start-page: 8531916 year: 2018 ident: 10.1016/j.ejrad.2023.111270_b0055 article-title: Contrast-Enhanced Mammography (CEM) for Detecting Residual Disease after Neoadjuvant Chemotherapy: A Comparison with Breast Magnetic Resonance Imaging (MRI) publication-title: Biomed Res Int. doi: 10.1155/2018/8531916 contributor: fullname: Barra – volume: 18 start-page: 851 issue: 1 year: 2018 ident: 10.1016/j.ejrad.2023.111270_b0130 article-title: RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial publication-title: BMC Cancer doi: 10.1186/s12885-018-4760-4 contributor: fullname: Heil – volume: 10 issue: 10 year: 2022 ident: 10.1016/j.ejrad.2023.111270_b0125 article-title: Contrast-Enhanced Mammography (CEM) Capability to Distinguish Molecular Breast Cancer Subtypes publication-title: Biomedicines. doi: 10.3390/biomedicines10102384 contributor: fullname: Luczynska |
SSID | ssj0005492 |
Score | 2.453951 |
Snippet | •CEM was found to be as accurate as MRI in predicting response to PST.•MRI predict the size of the residual tumor more accurately than CEM.•Some lesions... To evaluate the accuracy of contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) in the assessing radiological response to primary systemic... PURPOSETo evaluate the accuracy of contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI) in the assessing radiological response to primary... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 111270 |
SubjectTerms | Breast cancer Complete response contrast-enhanced mammography (CEM) Primary systemic therapy Residual lesion |
Title | Is contrast-enhanced mammography (CEM) an alternative to MRI in assessing the response to primary systemic therapy of breast cancer? |
URI | https://dx.doi.org/10.1016/j.ejrad.2023.111270 https://www.ncbi.nlm.nih.gov/pubmed/38141263 https://search.proquest.com/docview/2905527397 |
Volume | 170 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELa6i4S4IN6Ul4zEAVSyam0nTk4ILYXNoRy2i4S4RE7salMtCcqDA2d-OONX0221CJC4RJXj1G7n82Q883kGoRdSxEWUFzQQkYgCxgsR5JESAVVxAgtEhFxph9vJkn_8HL-bs_lo5CtrDm3_VdLQBrLWJ2f_QtqbL4UG-AwyhytIHa5_JPe0tfRz0XaBqs5tgP-rgAnY3NQmbDtfaG8ALG0TLK9s8m-wQhenqXaACBMJ9gepGkujNR2-ueQUNgF0WUzs-S0Tps81v73TNLICcLBDGNx2-jsDuBGyvOTUX_aVVYJpNTAb01bk6mLyQdc8Ejo8Ao_ZoznVQDJq-h-T47KxxN9lefG93NxzDy5EU3e1PxHuloTzdhC24-3YP4ZjNCUnmqNqahTDS81q8pibrQO_pOptkZK914b1YKyP1Bp-w5GuKK9fJcT23snHvdSj6cGIzvQfM3qArhHQclrJfglPB34RMxW5N3PzKa8MuXBvoKvMoqu2Pcb8ObuFbrp9C35rAXcbjVR1B11fOGbGXfQzbfEe7vAW7vBLQN0rLCq8hTnc1Rgwh0to9ZjDACnsMac7OMxhjznsMIfrFbaYwxZzb-6hT-_nZ8cngavwERR0mnSBVJKp6SoWCaiKnKoEdq9yynOZJ6yIKGO5DjvTmCdgQjGpxCwWPFch9J9JCUbXfXRY1ZV6iLCAnT8hnBQqZAx0TkyjUK4SGurU-Dwuxui1_4MzN-_MMxzXmZFHpuWRWXmMUeSFkDlb1NqYGWDm9w8-9yLLQFPr8JuoVN23GUmmJt1hwsfogZXlZiZgN7MZieijfx32MboxLJcn6LBrevUUHbSyf2Zg-Qu4r8Ku |
link.rule.ids | 315,782,786,27933,27934 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Is+contrast-enhanced+mammography+%28CEM%29+an+alternative+to+MRI+in+assessing+the+response+to+primary+systemic+therapy+of+breast+cancer%3F&rft.jtitle=European+journal+of+radiology&rft.au=Sunen%2C+Ines&rft.au=Isabel+Garcia+Barrado%2C+Ana&rft.au=Cruz+Ciria%2C+Silvia&rft.au=Garcia+Maroto%2C+Julian&rft.date=2024-01-01&rft.pub=Elsevier+B.V&rft.issn=0720-048X&rft.eissn=1872-7727&rft.volume=170&rft_id=info:doi/10.1016%2Fj.ejrad.2023.111270&rft.externalDocID=S0720048X23005843 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0720-048X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0720-048X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0720-048X&client=summon |